Product Information
RAMELTEON 8 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.6598 per EA under NDC 00591219130. Its NADAC has been published 368 times since Sep 18, 2019.
FDA first approved this application on Aug 19, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591219130
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RAMELTEONApproval Type
Generic (ANDA)
FDA Application
ANDA091610FDA Approved
8/19/2015
TE Code
AB
On Market Since
7/22/2019
Pharmacological Classes
Price Statistics
The NADAC for RAMELTEON 8 MG TABLET has been published 368 times since Sep 18, 2019, and over the history we have for it it has declined 78.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6598 per EA |
|---|---|
| All-time high | $3.5757 (Mar 11, 2020) |
| All-time low | $0.5491 (Nov 20, 2024) |
| 52-week high | $0.7622 |
| 52-week low | $0.6575 |
| Median price | $1.0063 |
| Average price | $1.5085 |
| Largest weekly change | +50.1% (Aug 21, 2024) |
| Weeks tracked | 368 |
| Tracking since | Sep 18, 2019 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ramelteon market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Melatonin Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RAMELTEON 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RAMELTEON 8 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.6598 per EA (NDC 00591219130), effective Sep 30, 2026.
How has the price of RAMELTEON 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for RAMELTEON 8 MG TABLET has declined 78.2%. It has been tracked across 368 weekly CMS publications since Sep 18, 2019.
What are the highest and lowest recorded NADAC prices for RAMELTEON 8 MG TABLET?
Since Sep 18, 2019, the NADAC for RAMELTEON 8 MG TABLET has ranged from a low of $0.5491 (Nov 20, 2024) to a high of $3.5757 (Mar 11, 2020), with a median of $1.0063 per EA.
Are there cheaper alternatives to RAMELTEON 8 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RAMELTEON 8 MG TABLET, is $0.6575 per EA — about 0% below RAMELTEON 8 MG TABLET.
Who manufactures RAMELTEON 8 MG TABLET?
RAMELTEON 8 MG TABLET (NDC 00591219130) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.